Objectives: To review clinical validation or implementation studies of maternal blood cell-free (cf) DNA analysis and define the performance of screening for fetal Trisomies 21, 18 and 13 and sex chromosome aneuploidies. Methods: Searches of PubMed, Embase and the Cochrane library were performed to identify all peer-reviewed articles on cfDNA testing in screening for aneuploidies between January 2011, when the first such study was published and 31 December 2016. Results: In total, 35 relevant studies were identified and these reported cfDNA results in relation to fetal karyotype from invasive testing or clinical outcome. In the combined total of 1,963 cases of Trisomy 21 and 225,032 non-Trisomy 21 singleton pregnancies the pooled weighted detection rate (DR) and false positive rate (FPR) were 99.7% (95% CI 99.1-99.9%) and 0.04% (95% CI 0.02-0.08%), respectively. In a total of 560 cases of Trisomy 18 and 212,019 unaffected singleton pregnancies the pooled weighted DR and FPR were 98.2% (95% CI 95.5-99.2%) and 0.05% (95% CI 0.03-0.07%). In a total of 119 cases of Trisomy 13 and 212,883 unaffected singleton pregnancies the pooled weighted DR and FPR were 99.0% (95% CI 65.8-100%) and 0.04% (95% CI 0.02-0.07%). In a total of 36 cases of monosomy X and 7,677 unaffected singleton pregnancies the pooled weighted DR and FPR were 95.8% (95% CI 70.3-99.5%) and 0.14% (95% CI 0.05-0.38%). In a combined total of 17 cases of sex chromosome abnormalities other than monosomy X and 5,383 unaffected singleton pregnancies the pooled weighted DR and FPR were 100% (95% CI 83.6-100%) and 0.003% (95% CI 0-0.07%). For twin pregnancies, in a total of 24 cases of Trisomy 21 and 1,111 unaffected cases the DR was 100% (95% 95.2-100%) and FPR was 0% (95% CI 0-0.003%). Conclusions: Screening by analysis of cfDNA in maternal blood in singleton pregnancies could detect >99% of fetuses with Trisomy 21, 98% of Trisomy 18 and 99% of Trisomy 13 at a combined FPR of 0.13%. The number of reported cases of sex chromosome abnormalities is too small for accurate assessment of performance of screening.
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OC15.02
Evolving role of ultrasound in the NIPT era: population-based trends in screening and diagnostic testing for fetal aneuploidy Objectives: To assess the population-wide impact of non-invasive prenatal testing (NIPT) on combined first trimester screening (CFTS), early ultrasound (11-13 weeks) and invasive prenatal diagnosis in a state with over 73,000 births pa. Methods: Analysis of population-based data from the Australian state of Victoria for the period 2000-2015 including (i) invasive prenatal tests (ii) CFTS uptake, (iii) 11-13 week ultrasounds, and (iv) total births. Utilisation of early ultrasound was analysed before and after NIPT (2010 NIPT ( -2015 . Results: The total number of diagnostic procedures performed < 25 weeks gestation during the 16-year study period was 62,536. Invasive testing decreased significantly by 39.6% from 2012 to 2015 despite steady births. CFTS uptake declined significantly in 2015 for the first time in its history, from 77.5% of all births in 2013 to 68.1% in 2015. Despite the decline in CFTS, the numbers of 11-13 week ultrasounds continued to rise and in 2015, ultrasound abnormality replaced CFTS as the most common indication for invasive testing (35% of all indications). Among those women that had an invasive test for an ultrasound abnormality in 2014-2015, diagnostic testing prior to 18 weeks gestation was associated with a significantly higher rate of major chromosome abnormality (32.6%, 173/532), compared with testing at 18-24 weeks gestation (12.5%, 94/750) ( p < 0.0001). More than half of all confirmed cases of Trisomy 21 were ascertained by NIPT in 2015, while comprising 11.7% of total indications for invasive testing. More than 85% of all invasive tests in 2015 were analysed by chromosomal microarray. Conclusions: In the NIPT era, ultrasound abnormality has displaced CFTS as the most common indication for invasive prenatal testing. However, NIPT is the screening test that precedes the majority of confirmed diagnoses of Trisomy 21. The contributions of NIPT, 11-13 week ultrasound and chromosome microarray has led to unprecedented detection rates of major chromosome abnormalities, now found in one in five invasive tests.
OC15.03
Comparison between first trimester combined screening and a combination between ultrasound and cell-free DNA Methods: Randomised prospective single centre study at the university of Tuebingen involving singleton pregnancies at 11-13 weeks. In all pregnancies, a first trimester anatomy scan was performed including measurement of the fetal NT. Pregnancies with NT >3.5mm or pregnancies with fetal defects underwent invasive testing and were not considered eligible for this study. The others were randomised accordingly. Women in study arm 1 had first trimester combined screening. Women in study arm 2 received cfDNA testing (Harmony Prenatal Test, Cenata, Germany). In order to provide a test result for those cases without cfDNA test result, a serum sample that was also taken at the time of the ultrasound examination. Primary outcome was the FPR in both arms which was defined as risk for Trisomy 21 of 1:100 or higher. The analysis followed an intention to treat approach. Results: Study arm 1 included 699 pregnancies, study arm 2 701, respectively. In study arm 1 and 2, median maternal age was 33.8 and 33.9 years, median CRL was 67.6 mm in both groups and median NT was 1.9 and 1.8mm, respectively. In study arm 2, in 11 (1.6%) pregnancies, the cfDNA analysis did not yield a result and a combined risk was calculated based on combined screening. The median risk in study arm 1 was 1:3,810. In 15 (2.2%) cases, the risk was above 1:100. All of those were false positive cases. In study arm 2, median risk was 1:10,000 and none of the risks was above 1:100 (chi square p<0.0001).
